ReviewCell division2026
The roles and clinical significance of LINC01140 in human cancers in the real world.
Review in Cell division, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinogenic factors facilitate cell carcinogenesis and the progression of cancer. In contrast, tumor suppressor factors inhibit abnormal cell proliferation and cancer development. Accumulating evidence indicates that long non-coding RNAs (lncRNAs) can either suppress or promote cancer initiation and progression. LINC01140, a recently identified lncRNA, exhibits abnormal expression in cancerous tissues. Downstream target genes can be regulated, directly or indirectly, via miRNAs (miR-452-5p, miR-139-5p, miR-140-5p, miR-33a, miR-4742-5p, miR-200b-3p, and miR-452-5p), functioning as either oncogenes or tumor suppressors and contributing to cancer progression. Dysregulated LINC01140 expression shows significant correlations with patient survival, diagnosis, and cancer stage. Consequently, this review aims to examine the expression patterns, functional roles, and clinical significance of LINC01140 across pan-cancer, highlighting it as a potential therapeutic target for cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.